207_Combined course Presentations

DAHANCA 10 – Cancer-specific and overall survival

DAHANCA 10

100

80

Control

65% 53%

60

Hazard ratio 1.41 (1.08-1.85)

Aranesp

40

p=0.01 multivariate p= 0.02

20

Cancer specific survival (%) 0

0 6 12 18 24 30 36 42 48 54 60

Time after treatment (months)

Overgaard et al ICHNO 2013

02